{"id":"W3039432873","doi":"10.1016/j.lungcan.2020.06.032","title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Ignyta; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; MacroGenics; Juno Therapeutics; Pfizer; Incyte; Kite Pharma; Spectrum Pharmaceuticals; Yuhan; Merck KGaA; Regeneron Pharmaceuticals; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Oncology; Cohort; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00483392,0.0004324078,0.001134289,0.0002394208,0.0002137247,0.001260211,0.0009538415,0.0007510977,0.002069041],"category_scores_gemma":[0.002354409,0.0001786118,0.001019605,0.0003033972,0.0002130419,0.0005753093,0.0004332239,0.001722625,0.0005947755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009538634,"about_ca_system_score_gemma":0.001103219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001186578,"about_ca_topic_score_gemma":0.003484697,"domain_scores_codex":[0.9992367,0.000281773,0.00005045143,0.00006558943,0.0002857327,0.00007968895],"domain_scores_gemma":[0.9977099,0.0004719823,0.0006131667,0.0001737388,0.0005466057,0.0004845966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1283777,0.005594337,0.05601438,0.002145037,0.003727389,0.0004904177,0.0002820454,0.003570179,0.04572155,0.001644255,0.1105547,0.6418781],"study_design_scores_gemma":[0.1649382,0.1492174,0.2749372,0.0008736551,0.006700837,0.00310243,0.0002032792,0.01017592,0.01793583,0.001893878,0.3698589,0.0001624211],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8919322,0.04134216,0.00643423,0.008390921,0.0008941604,0.001944946,0.02039072,0.0006487254,0.02802198],"genre_scores_gemma":[0.9047844,0.01264338,0.009645607,0.0124894,0.0008949646,0.00228784,0.0483542,0.0002150434,0.008685142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00483392,"threshold_uncertainty_score":0.02556455,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356613840783815,"score_gpt":0.387555711866924,"score_spread":0.3539895734590858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}